Cell-wall preparation containing poly-γ- d -glutamate covalently linked to peptidoglycan, a straightforward extractable molecule, protects mice against experimental anthrax infection

Highlights ► Bacillus anthracis peptidoglycan-linked poly-glutamate (GluPG) is a potent antigen. ► GluPG + FIS partially protects mice against an encapsulated B. anthracis challenge. ► GluPG + PA fully protects mice against a B. anthracis virulent strain challenge.

Saved in:
Bibliographic Details
Published in:Vaccine 2012-12, Vol.31 (1), p.171-175
Main Authors: Candela, Thomas, Dumetz, Fabien, Tosi-Couture, Evelyne, Mock, Michèle, Goossens, Pierre L, Fouet, Agnès
Format: Article
Language:English
Subjects:
Acellular vaccine
Allergy and Immunology
animal models
Animals
anthrax
Anthrax - immunology
Anthrax - prevention & control
Anthrax Vaccines - chemistry
Anthrax Vaccines - therapeutic use
antibodies
antigens
Antigens, Bacterial - chemistry
Antigens, Bacterial - immunology
Applied microbiology
Bacillus anthracis
Bacillus anthracis - chemistry
Bacillus anthracis - pathogenicity
Bacteriology
Biological and medical sciences
Cell Wall - chemistry
Female
Fundamental and applied biological sciences. Psychology
humans
immune response
immunization
live vaccines
Mice
Microbiology
Microscopy, Electron, Transmission
Miscellaneous
Peptidoglycan
Peptidoglycan - chemistry
peptidoglycans
Poly-γ-d-glutamate capsule
Polyglutamic Acid - analogs & derivatives
Polyglutamic Acid - chemistry
Protective antigen
protective effect
septicemia
toxemia
Vaccines, antisera, therapeutical immunoglobulins and monoclonal antibodies (general aspects)
virulent strains
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Highlights ► Bacillus anthracis peptidoglycan-linked poly-glutamate (GluPG) is a potent antigen. ► GluPG + FIS partially protects mice against an encapsulated B. anthracis challenge. ► GluPG + PA fully protects mice against a B. anthracis virulent strain challenge.
ISSN:0264-410X
1873-2518
DOI:10.1016/j.vaccine.2012.10.071